NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

Company Overview

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.85 to $2.14
• 50-Day Range: $1.60 to $2.60
• 52-Week Range: $2.08 to $6.75
• Volume: 67,359 shs
• Average Volume: 397,830 shs
• Market Capitalization: $17.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

NeuroBo Pharmaceuticals Stock Analysis - MarketRank™

NeuroBo Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat, and ranked 868th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeuroBo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeuroBo Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($3.91) to ($1.33) per share.

Price to Book Value per Share Ratio

NeuroBo Pharmaceuticals has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NRBO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroBo Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NeuroBo Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NRBO.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for NeuroBo Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added NeuroBo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.05% of the stock of NeuroBo Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions.

NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed this year?

NeuroBo Pharmaceuticals' stock was trading at $2.03 at the beginning of the year. Since then, NRBO stock has decreased by 2.5% and is now trading at $1.98.
View the best growth stocks for 2025 here.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.27.

When did NeuroBo Pharmaceuticals' stock split?

Shares of NeuroBo Pharmaceuticals reverse split before market open on Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), General Electric (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/30/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Banking
• Current Symbol: NASDAQ:NRBO
• CUSIP: N/A
• CIK: 1638287
• Web: www.neurobopharma.com
• Phone: (857) 702-9600
• Fax: 734-293-0444
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +405.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -189.12%
• Return on Assets: -122.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 8,616,000
• Free Float: 8,526,000
• Market Cap: $17.06 million
• Optionable: Not Optionable
• Beta: -0.26